{"organizations": [], "uuid": "0ab3070a3c8bb716c81b5f889693d8dc804c6706", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180328.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-alkem-laboratories-gets-form-483-w/brief-alkem-laboratories-gets-form-483-with-13-observations-after-u-s-fda-inspection-at-cos-amaliya-facility-idUSFWN1RA068", "country": "US", "domain_rank": 408, "title": "BRIEF-Alkem Laboratories Gets Form 483 With 13 Observations After U.S. FDA Inspection At Co's Amaliya Facility​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.997, "site_type": "news", "published": "2018-03-28T15:30:00.000+03:00", "replies_count": 0, "uuid": "0ab3070a3c8bb716c81b5f889693d8dc804c6706"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-alkem-laboratories-gets-form-483-w/brief-alkem-laboratories-gets-form-483-with-13-observations-after-u-s-fda-inspection-at-cos-amaliya-facility-idUSFWN1RA068", "ord_in_thread": 0, "title": "BRIEF-Alkem Laboratories Gets Form 483 With 13 Observations After U.S. FDA Inspection At Co's Amaliya Facility​", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}, {"name": "amaliya", "sentiment": "none"}, {"name": "co", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "alkem laboratories ltd", "sentiment": "negative"}, {"name": "u.s. fda inspection at co", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "fda at co's st louis", "sentiment": "none"}, {"name": "ection", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28 (Reuters) - Alkem Laboratories Ltd:\n* GOT A FORM 483 WITH 13 OBSERVATIONS AFTER US FDA INSPECTION AT CO’S MANUFACTURING FACILITY AT AMALIYA, DAMAN​\n* SAYS ‍ US FDA HAD CONDUCTED INSPECTION AT THE FACILITY FROM MARCH 19-27\n* SHALL PUT TOGETHER DETAILED RESPONSE WITH ADEQUATE CORRECTIVE AND PREVENTIVE MEASURES TO ADDRESS US FDA OBSERVATIONS​\n* ‍IN RESPONSE TO FORM 483 BY FDA AT CO'S ST LOUIS FACILITY, CO HAS SUBMITTED CORRECTIVE AND PREVENTIVE ACTION PLAN ​ Source text: bit.ly/2I9G2xd Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2I9G2xd", "https://instagram.com/reuters/"], "published": "2018-03-28T15:30:00.000+03:00", "crawled": "2018-03-29T15:42:40.111+03:00", "highlightTitle": ""}